Success Metrics

Clinical Success Rate

62.5%

Based on 5 completed trials

Completion Rate

63%(5/8)

Active Trials

0(0%)

Results Posted

140%(7 trials)

Terminated

3(27%)

Phase Distribution

Ph phase_2

36%

Ph phase_1

64%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution11 total trials

Phase 1Safety & dosage

7(63.6%)

Phase 2Efficacy & side effects

4(36.4%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

45.5%

5 of 11 finished

Non-Completion Rate

54.5%

6 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(5)

Terminated(6)

Detailed Status

Completed5

Terminated3

Withdrawn3

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

62.5%

Most Advanced

Phase 2

Trials by Phase

Phase 17 (63.6%)

Phase 24 (36.4%)

Trials by Status

terminated327%

completed545%

withdrawn327%

Recent Activity

0 active trials

Showing 5 of 11

completedphase_2

Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)

NCT03648489

completedphase_1

Evaluation of the Safety and Tolerability of TAK-228 With TAK-117 and Paclitaxel in Advanced Solid Tumors

NCT03154294

completedphase_2

Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma

NCT03097328

terminatedphase_1

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of TAK-228 as Single Agent in Adult East Asian Participants With Advanced Nonhematological Malignancies

NCT03370302

terminatedphase_2

Study of TAK-228 (MLN0128) in Soft Tissue Sarcomas

NCT02987959

View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials

NCT03648489Phase 2

Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)

Completed

NCT03154294Phase 1

Evaluation of the Safety and Tolerability of TAK-228 With TAK-117 and Paclitaxel in Advanced Solid Tumors

Completed

NCT03097328Phase 2

Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma

Completed

NCT03370302Phase 1

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of TAK-228 as Single Agent in Adult East Asian Participants With Advanced Nonhematological Malignancies

Terminated

NCT02987959Phase 2

Study of TAK-228 (MLN0128) in Soft Tissue Sarcomas

Terminated

NCT02988986Phase 2

TAK-228 Plus Tamoxifen in Patients With ER-Positive, HER2-negative Breast Cancer

Completed

NCT02727777Phase 1

Phase II Study of TAK228 in Relapsed Lymphoma

Terminated

NCT02619669Phase 1

Neoadjuvant Run-In Study With TAK-228 Followed by Letrozole/TAK-228 in Women With High-Risk ER+/HER2- Breast Cancer

Withdrawn

NCT01899053Phase 1

A Safety and Pharmacokinetic Study of TAK-228 in Combination With TAK-117 in Adult Participants With Advanced Nonhematologic Malignancies

Completed

NCT03205891Phase 1

Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma and Other CD30+Peripheral T-Cell Lymphomas

Withdrawn

NCT02812056Phase 1

Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies

Withdrawn

All 11 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 11